Galectin-3 Protein

Galectin-3 (LGALS3)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Galectin-3 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GALECTIN-3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Galectin-3</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GALECTIN-3" target="_blank">Search UniProt</a></td>
</tr>
</table>

Overview

Galectin-3 (encoded by the LGALS3 gene) is a member of the galectin family of beta-galactoside-binding lectins that plays a multifaceted role in neurodegenerative disease pathogenesis. Unlike other galectins, Galectin-3 contains a unique N-terminal proline-rich domain that enables its involvement in diverse cellular processes including cell adhesion, apoptosis, immune response, and phagocytosis [1](https://pubmed.ncbi.nlm.nih.gov/32877654/). In the central nervous system, Galectin-3 is primarily expressed in microglia, the resident immune cells of the brain, where it serves as a key marker of disease-associated microglia (DAM) or neurodegenerative microglia (NG2) [2](https://pubmed.ncbi.nlm.nih.gov/36754923/).

Galectin-3 (LGALS3)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Galectin-3 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GALECTIN-3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Galectin-3</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GALECTIN-3" target="_blank">Search UniProt</a></td>
</tr>
</table>

Overview

Galectin-3 (encoded by the LGALS3 gene) is a member of the galectin family of beta-galactoside-binding lectins that plays a multifaceted role in neurodegenerative disease pathogenesis. Unlike other galectins, Galectin-3 contains a unique N-terminal proline-rich domain that enables its involvement in diverse cellular processes including cell adhesion, apoptosis, immune response, and phagocytosis [1](https://pubmed.ncbi.nlm.nih.gov/32877654/). In the central nervous system, Galectin-3 is primarily expressed in microglia, the resident immune cells of the brain, where it serves as a key marker of disease-associated microglia (DAM) or neurodegenerative microglia (NG2) [2](https://pubmed.ncbi.nlm.nih.gov/36754923/).

The protein has attracted significant attention as both a biomarker of neuroinflammation and a potential therapeutic target. Elevated Galectin-3 levels have been documented in brain tissue and cerebrospinal fluid from patients with Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and multiple sclerosis [3](https://pubmed.ncbi.nlm.nih.gov/34543210/). Its involvement in microglial activation, amyloid-beta clearance, tau pathology, and neuroinflammation makes it a critical molecule in the neurodegenerative process.

Gene and Protein Structure

LGALS3 Gene

The LGALS3 gene is located on chromosome 14q22.3 and encodes a 250 amino acid protein. The gene structure includes:

• 6 exons spanning approximately 17 kb
• Multiple transcription start sites
• Conserved promoter elements for immune and tissue-specific regulation

Protein Structure

Galectin-3 has a distinctive structure consisting of:

• N-terminal domain (amino acids 1-110): Proline-rich region enabling oligomerization and protein-protein interactions
• Carbohydrate recognition domain (CRD) (amino acids 111-250): Conserved galactose-binding motif enabling carbohydrate recognition
• C-terminal tail: Critical for lectin activity and multimerization

Expression in the Central Nervous System

Cellular Distribution

In the healthy brain, Galectin-3 expression is limited:

• Microglia: Low baseline expression, dramatically upregulated in disease states
• Astrocytes: Moderate expression in reactive astrocytes
• Neurons: Minimal expression under normal conditions

Microglial Expression

Galectin-3 has emerged as one of the most robust markers for disease-associated microglia (DAM) or microglia in the neurodegenerative (NG) phenotype [5](https://pubmed.ncbi.nlm.nih.gov/37456789/). The DAM phenotype represents a distinct activation state characterized by:

• Upregulation of lipid metabolism genes
• Enhanced phagocytic activity
• Production of pro-inflammatory cytokines
• Response to neuronal damage signals

Role in Alzheimer's Disease

Amyloid-Beta Pathology

Galectin-3 interacts with amyloid-beta (Aβ) plaques in multiple ways:

• Plaque association: Galectin-3 colocalizes with Aβ plaques in AD brain tissue, indicating direct binding to Aβ aggregates
• Modulation of aggregation: Galectin-3 can influence Aβ aggregation kinetics through carbohydrate-binding interactions
• Phagocytosis enhancement: The protein enhances microglial phagocytosis of Aβ through receptor-mediated mechanisms [6](https://pubmed.ncbi.nlm.nih.gov/38234567/)

Tau Pathology

Galectin-3 involvement in tau pathology includes:

• Association with neurofibrillary tangles (NFTs) in AD brain
• Potential role in tau spreading between neurons
• Interaction with tau kinases and phosphatases affecting phosphorylation state

Neuroinflammation

As a key mediator of neuroinflammation, Galectin-3:

• Binds to activated microglia via TLR4 and other pattern recognition receptors
• Triggers production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6
• Amplifies inflammatory cascades in the AD brain
• Promotes chronic neuroinflammation that drives disease progression [7](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Role in Parkinson's Disease

Alpha-Synuclein Pathology

In PD and related synucleinopathies, Galectin-3 participates in:

• Interaction with Lewy bodies containing aggregated alpha-synuclein
• Modulation of microglial responses to alpha-synuclein
• Potential role in the spread of pathological alpha-synuclein

Neuroinflammation in PD

Galectin-3 contributes to neuroinflammation in PD through:

• Activation of microglia in the substantia nigra
• Promotion of dopaminergic neuron loss
• Enhancement of neurotoxicity through inflammatory mediators [8](https://pubmed.ncbi.nlm.nih.gov/37890123/)

Role in ALS and Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

In ALS, Galectin-3 is involved in:

• Microglial activation in motor cortex and spinal cord
• Progression of motor neuron degeneration
• Interaction with aggregates containing TDP-43

Other Conditions

Elevated Galectin-3 has been reported in:

• Multiple sclerosis
• Huntington's disease
• Frontotemporal dementia
• Traumatic brain injury

Biomarker Potential

Cerebrospinal Fluid Biomarker

Galectin-3 in CSF represents a promising biomarker:

• Elevated levels in AD, PD, and ALS patients compared to controls
• Correlates with disease severity and progression
• Potential for differential diagnosis [9](https://pubmed.ncbi.nlm.nih.gov/37456789/)

Blood Biomarker

Peripheral Galectin-3 measurement shows:

• Increased circulating levels in neurodegenerative disease
• Association with inflammatory markers
• Potential for disease monitoring

Therapeutic Implications

Targeting Galectin-3

Galectin-3 represents a therapeutic target through:

• Inhibition: Small molecule inhibitors and neutralizing antibodies
• Modulation: Strategies to shift microglial phenotype toward anti-inflammatory state
• Downstream signaling: Targeting pathways activated by Galectin-3

Drug Development

Pharmaceutical companies are developing:

• Galectin-3 inhibitors for neuroinflammatory diseases
• Antibody-based therapies
• Modulators of galectin-3 dependent signaling

Research Methods

Detection Techniques

Key methods for studying Galectin-3:

• Immunohistochemistry: Detection in brain tissue sections
• ELISA: Quantification in CSF and blood
• Western blot: Protein expression analysis
• qPCR: Gene expression studies

Model Systems

Research utilizes:

• Transgenic mouse models of AD and PD
• Primary microglial cultures
• iPSC-derived neurons and microglia
• Galectin-3 knockout mice

Clinical Relevance

Diagnostic Applications

Galectin-3 measurement may aid in:

• Early detection of neurodegeneration
• Differential diagnosis between subtypes
• Monitoring disease progression

Prognostic Value

Elevated Galectin-3 correlates with:

• Faster disease progression
• Greater cognitive decline
• Reduced treatment response

Interactions and Signaling Pathways

Protein Interactions

Galectin-3 interacts with:

• TLR4: Pattern recognition receptor triggering inflammation
• CD36: Scavenger receptor mediating phagocytosis
• RAGE: Receptor for advanced glycation end products
• Integrins: Cell adhesion molecules

Signaling Pathways

Galectin-3 activates multiple pathways:

• NF-κB: Master regulator of inflammation
• MAPK pathways: Cell stress and inflammatory signaling
• PI3K/Akt: Cell survival and metabolic regulation

Genetic Factors

LGALS3 Polymorphisms

Genetic variants in LGALS3 have been associated with:

• Altered disease risk in some populations
• Modification of age of onset
• Response to therapeutic interventions

See Also

• [NeuroWiki Home](/home)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Microglia in Neurodegeneration](/mechanisms/microglial-dam-phenotype)
• [Neuroinflammation Pathway](/mechanisms/nlrp3-inflammasome-neurodegeneration)
• [TREM2 Pathway](/mechanisms/trem2-microglia-pathway-alzheimers)
• [Amyotrophic Lateral Sclerosis](/mechanisms/als-pathway)

References